Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Published	Pages	Publisher	Report code
Mar 2022	36	Global Markets Direct	ASDR-599155

Published: Mar 2022 - Pages : 36 - Publisher : Global Markets Direct - Report code : ASDR-599155

AstraZeneca Plc
IMPACT Therapeutics Inc
InteRNA Technologies BV
Merck KGaA
Shuttle Pharmaceuticals Inc
XRad Therapeutics Inc